Technology Assessment: Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy, Part 4. Thalidomide for Multiple Myeloma. Table 12a

You Are Here: AHRQ Archive Home > Technology Assessment Archive > Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Table 12a. Predictors of Disease Response or Survival—Patient Demographic Factors that Predict Response to Thalidomide: Summary

Prognostic Factor	Number of studies indicating significant correlation with tumor response/ total number of studies indicating factor	Number of studies indicating significant correlation with survival/ total number of studies indicating factor
Age	Correlation with response=2/3 (Barlogie, 2002109;Yakoub-Agha, 2002⁶⁰) No correlation=1/3 (Shaughnessy, 2003¹³³)	Correlation with survival=3/3 (Mileshkin, Biagi, et al., 2003⁹⁹; Shaughnessy, 2003¹³³; Yakoub-Agha, 2002⁶⁰)
Gender		Correlation with survival=1/1 (Dimopoulos, 2004⁹⁴)
Performance status (PS measured on the ECOG PS scale)	Correlation with response=1/1 (Dimopoulos, 2001⁷⁰)	Correlation with survival=2/2 (Dimopoulos, 2001⁷⁰; Dimopoulos, 2004⁹⁴)
% of plasma cells in the BM		Correlation with survival=1/1 (Singhal, 1999³⁵)
Relapsed vs. refractory disease	Correlation with response=1/1 (Garcia-Sanz, 2004⁹⁵)
Time from diagnosis to onset of Thal	Correlation with response=1/1 (Yakoub-Agha, 2002⁶⁰)

Return to Document
Proceed to Table 12b

The information on this page is archived and provided for reference purposes only.